M. Franco G. Salvoza

Array ( [id] => 18329231 [patent_doc_number] => 11634459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Chimeric reporter West Nile/dengue viruses and their use [patent_app_type] => utility [patent_app_number] => 16/639652 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 13877 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 236 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13623039 [patent_doc_number] => 20180363071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => METHOD FOR DETECTING INFECTIOUS PARVOVIRUS IN PHARMACEUTICAL PREPARATIONS [patent_app_type] => utility [patent_app_number] => 16/100493 [patent_app_country] => US [patent_app_date] => 2018-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14258 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16230743 [patent_doc_number] => 10738283 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-11 [patent_title] => Oncolytic adenoviruses with increased proportion of the 156R splicing isoform of the E1B protein [patent_app_type] => utility [patent_app_number] => 16/030204 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 15238 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16030204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13533739 [patent_doc_number] => 20180318412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => INACTIVATED VARICELLA ZOSTER VIRUS VACCINES, METHODS OF PRODUCTION, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/026779 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622081 [patent_doc_number] => 20180362592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => NOVEL AAV'S AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/019636 [patent_app_country] => US [patent_app_date] => 2018-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16019636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282683 [patent_doc_number] => 20200276285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => A METHOD TO CREATE PERSONALIZED CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 16/617805 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39711 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206331 [patent_doc_number] => 20190365852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => RECOMBINANT BACULOVIRUSES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/992178 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15992178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16246132 [patent_doc_number] => 10745474 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-18 [patent_title] => Methods of treating inflammation associated airway diseases and viral infections [patent_app_type] => utility [patent_app_number] => 15/986382 [patent_app_country] => US [patent_app_date] => 2018-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 44 [patent_no_of_words] => 14265 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15986382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20077759 [patent_doc_number] => 12351812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Recombinant oncolytic virus [patent_app_type] => utility [patent_app_number] => 16/614441 [patent_app_country] => US [patent_app_date] => 2018-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 5969 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16614441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17207770 [patent_doc_number] => 11168129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-09 [patent_title] => Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 16/611399 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 23 [patent_no_of_words] => 22796 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18716550 [patent_doc_number] => 11793873 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Bivalent dengue/hepatitis B vaccines [patent_app_type] => utility [patent_app_number] => 16/612152 [patent_app_country] => US [patent_app_date] => 2018-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 6981 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18232135 [patent_doc_number] => 11596679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Hepatitis C virus gene sequences and methods of use therefor [patent_app_type] => utility [patent_app_number] => 16/608308 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 8 [patent_no_of_words] => 18330 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15481343 [patent_doc_number] => 10555997 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-11 [patent_title] => Antigens and vaccines directed against human enteroviruses [patent_app_type] => utility [patent_app_number] => 15/964198 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 18062 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175560 [patent_doc_number] => 20200222528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus [patent_app_type] => utility [patent_app_number] => 16/608392 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15466221 [patent_doc_number] => 10548964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => Antigens and vaccines directed against human enteroviruses [patent_app_type] => utility [patent_app_number] => 15/964211 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 17728 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666531 [patent_doc_number] => 11773409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors [patent_app_type] => utility [patent_app_number] => 16/607029 [patent_app_country] => US [patent_app_date] => 2018-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 41 [patent_no_of_words] => 27529 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 230 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13354719 [patent_doc_number] => 20180228899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 15/956099 [patent_app_country] => US [patent_app_date] => 2018-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15265 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15956099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16492604 [patent_doc_number] => 10858631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-08 [patent_title] => Methods for adeno-associated viral vector production [patent_app_type] => utility [patent_app_number] => 15/955992 [patent_app_country] => US [patent_app_date] => 2018-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 14 [patent_no_of_words] => 25406 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15955992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681885 [patent_doc_number] => 20200095606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => STABLE CELL LINES FOR RETROVIRAL PRODUCTION [patent_app_type] => utility [patent_app_number] => 16/606281 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19027492 [patent_doc_number] => 11926839 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => Platform for T lymphocyte genome engineering and in vivo high-throughput screening thereof [patent_app_type] => utility [patent_app_number] => 16/605715 [patent_app_country] => US [patent_app_date] => 2018-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 112 [patent_figures_cnt] => 159 [patent_no_of_words] => 33565 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16605715 [rel_patent_id] =>[rel_patent_doc_number] =>)